Amotiv Limited Total Assets
Amotiv Limited total assets. Based on the latest financial reports, Amotiv Limited (AOV) holds total assets worth CA$1.05 Billion CAD (≈ $756.88 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AOV stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Amotiv Limited (2013–2025)
Total assets of Amotiv Limited from 2013 to 2025. This chart illustrates how Amotiv Limited's total assets have evolved over time, based on quarterly financial data. See AOV live share price for real-time trading data and today's change.
Amotiv Limited - Asset Composition Analysis
Amotiv Limited Total Assets Breakdown (December 2025)
Amotiv Limited total assets breakdown as of December 2025. Amotiv Limited's total assets of CA$1.05 Billion consist of 37.7% current assets and 62.3% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$5.35 Million | 6.8% |
| Accounts Receivable | CA$127.78 Million | 12.2% |
| Inventory | CA$135.87 Million | 13.0% |
| Property, Plant & Equipment | CA$21.93 Million | 2.1% |
| Intangible Assets | CA$379.51 Million | 36.3% |
| Goodwill | CA$89.98 Million | 8.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Amotiv Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Amotiv Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amotiv Limited's current assets represent 37.7% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 36.3% of total assets.
Amotiv Limited Competitors by Total Assets
Key competitors of Amotiv Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Amotiv Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 3.57 | 4.86 |
| Quick Ratio | 1.57 | 2.64 | 4.37 |
| Cash Ratio | 0.03 | 0.05 | 0.00 |
| Working Capital | CA$229.57 Million | CA$285.56 Million | CA$440.58 Million |
Amotiv Limited - Advanced Valuation Insights
This section examines the relationship between Amotiv Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | CA$1.05 Billion |
| Market Capitalization | $576.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Amotiv Limited's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Amotiv Limited's assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Amotiv Limited (2013–2025)
The table below shows the annual total assets of Amotiv Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$1.05 Billion ≈ $756.88 Million |
+8.56% |
| 2024-12-31 | CA$963.80 Million ≈ $697.20 Million |
+1.94% |
| 2023-12-31 | CA$945.49 Million ≈ $683.96 Million |
-10.37% |
| 2022-12-31 | CA$1.05 Billion ≈ $763.05 Million |
+6.35% |
| 2021-12-31 | CA$991.89 Million ≈ $717.52 Million |
-4.60% |
| 2020-12-31 | CA$1.04 Billion ≈ $752.09 Million |
-20.35% |
| 2019-12-31 | CA$1.31 Billion ≈ $944.24 Million |
+24.10% |
| 2018-12-31 | CA$1.05 Billion ≈ $760.88 Million |
+4.56% |
| 2017-12-31 | CA$1.01 Billion ≈ $727.71 Million |
+1.54% |
| 2016-12-31 | CA$990.77 Million ≈ $716.71 Million |
+52.66% |
| 2015-12-31 | CA$648.99 Million ≈ $469.47 Million |
+33.37% |
| 2014-12-31 | CA$486.61 Million ≈ $352.01 Million |
+48661317000.00% |
| 2013-12-31 | CA$1.00 ≈ $0.72 |
-- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more